Company Description
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.
It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy that is in Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942 and SGX945, an innate defense regulator technology for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer and aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology which is in Phase IIa study to treat mild-to-moderate psoriasis.
Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate; SGX943, a therapeutic candidate for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola.
The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009.
Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jun 15, 1987 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Christopher Schaber |
Contact Details
Address: 29 Emmons Drive, Suite B-10 Princeton, New Jersey 08540 United States | |
| Phone | 609 538 8200 |
| Website | soligenix.com |
Stock Details
| Ticker Symbol | SNGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000812796 |
| CUSIP Number | 834223307 |
| ISIN Number | US8342235053 |
| Employer ID | 41-1505029 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher J. Schaber Ph.D. | Chairman of the Board of Directors, Chief Executive Officer and President |
| Jonathan L. Guarino CPA, CGMA | Senior Vice President, Chief Financial Officer and Corporate Secretary |
| Dr. Oreola Donini Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Richard C. Straube M.D., MSc. | Senior Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 8-K | Current Report |
| Mar 26, 2025 | EFFECT | Notice of Effectiveness |
| Mar 26, 2025 | EFFECT | Notice of Effectiveness |
| Mar 26, 2025 | EFFECT | Notice of Effectiveness |
| Mar 21, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 21, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 21, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 21, 2025 | 10-K | Annual Report |
| Feb 10, 2025 | 8-K | Current Report |
| Nov 8, 2024 | 424B3 | Prospectus |